Biotechnology

MicuRx

MicuRx released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 42.06 M, actual EPS CNY -0.03

MicuRx FY2026 Q1 Earnings Release Scheduled for April 29 After-Market BJT

MicuRx to Release FY2025 Earnings on March 28 After-Market (BJT), Forecast Revenue CNY 179 M, EPS CNY -0.58

MicuRx released FY2025 Q4 earnings on February 26 After-Market (BJT), actual revenue CNY 37.79 M, actual EPS CNY -0.071

MicuRx released FY2025 Annual Earnings on February 26 After-Market (BJT), actual revenue CNY 141.77 M (forecast CNY 179 M), actual EPS CNY -0.37 (forecast CNY -0.58)

MicuRx released FY2025 Q3 earnings on October 27 After-Market (BJT), actual revenue CNY 37.02 M, actual EPS CNY -0.0892

MicuRx released FY2025 9 Months Earnings on October 27 After-Market BJT, actual revenue CNY 103.99 M, actual EPS CNY -0.3004

MicuRx to Release FY2025 Q3 Earnings Report on October 28 After-Market BJT

MicuRx released FY2025 Q2 earnings on August 19 After-Market (BJT), actual revenue CNY 33.75 M, actual EPS CNY -0.1211

MicuRx released FY2025 Semi-Annual earnings on August 19 After-Market (BJT), actual revenue CNY 66.97 M, actual EPS CNY -0.21

MicuRx to Release FY2025 Semi-Annual Earnings on August 20, 2025 (BJT)

Concord Medical Holding Q1 2025 Financial Results Earnings Call

Allition Pharmaceutical's Conivaptan Sodium Injection New Drug Application Accepted for Review

MicroPort Therapeutics narrows net loss in Q1 2025

MicuRx released FY2025 Q1 earnings on April 23 After-Market BJT, actual revenue CNY 33.22 M, actual EPS CNY -0.09

MicuRx to Release FY2025 Q1 Earnings Report on April 24 After-Market BJT

MicuRx released FY2024 earnings on March 17, 2025 (BJT), actual revenue CNY 130.27 M (forecast CNY 156 M), actual EPS CNY -0.67 (forecast CNY -0.61)

MicuRx released FY2024 Q4 earnings on March 17, 2025 (BJT) with actual revenue of CNY 32.71 M and EPS of CNY -0.2316

MicuRx to Release FY2024 Annual Earnings on March 18, 2025 (BJT), Forecast Revenue 156 M CNY, EPS -0.61 CNY

Aikang Pharmaceutical Receives Clinical Trial Approval for MRX-5 Tablets to Treat Non-Tuberculous Mycobacterial Infections

588250

159992

688331

688373

In 2025, A-share biopharmaceutical companies are gradually moving from the "cash-burning R&D" stage to a new phase of "profit realization," benefiting from improved industry prosperity and policy support. As of March 29, over 70 biopharmaceutical companies have released their earnings. Among them, 61 companies achieved profitability, 29 companies saw year-on-year positive growth in net profit attributable to the parent company, and 7 companies doubled their profits. Furthermore, companies like RemeGen and InnoCare Pharma are expected to turn losses into profits, while companies such as MicuRx and Junshi Biosciences have reduced their losses

Wallstreetcn

Penghua SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

RemeGen

China Merchants CSI Biotechnology Theme ETF

REMEGEN

Tianhong CNI BIOMEDICINE ETF

InnoCare Pharma

JUNSHI BIO

Junshi Biosciences

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

INNOCARE

ChinaAMC CSI Biotechnology Theme ETF

Strong Growth in Innovative Drug Revenue, Biopharmaceutical Companies' Performance Shows High "Innovation" Content

MicuRx announced that its revenue for the third quarter was 37.0155 million yuan, a year-on-year increase of 0.52%; the net profit loss was 54.8617 million yuan. The revenue for the first three quarters was 104 million yuan, a year-on-year increase of 6.58%; the net profit loss was 194 million yuan

Zhitong

MicuRx: Net loss of 54.8617 million yuan in the third quarter

According to MicuRx, recently, MicuRx officially signed the "ADC Drug Joint Development Strategic Cooperation Agreement" with Nanjing Pengbo Biotechnology Co., Ltd. Both parties will fully leverage their respective advantages in the "toxin-linker" platform and the "antibody development platform" to jointly discover, research, and develop several innovative targeted antibody-drug conjugates

MicuRx Pharmaceuticals has reached a strategic cooperation agreement with Pengbo Biotech for the joint development of ADC drugs

MicuRx's shareholder Genie Pharma has proposed to add an interim proposal at the second extraordinary general meeting of shareholders in 2025, involving the removal of directors ZHENGYU YUAN, Li Zhile, Wu Pancheng, and the election of new directors Yang Zongfan, Wang Yong, and Xu Yuchao. The general meeting of shareholders originally scheduled for October 9, 2025, will review all proposals, including the new proposal

MicuRx shareholders Genie Pharma propose to add a temporary proposal regarding the removal and election of directors

MicuRx's shareholder Genie Pharma voted against several proposals for the second extraordinary general meeting in 2025, holding 71.5728 million shares, accounting for 10.92% of the total shares. The solicitation period for voting rights is from September 25, 2025, to October 6, 2025. Reasons for opposition include the uncertainty of funds from Haiqing Pharmaceutical's private placement, risks of mixed sales channels, and the progress of fundraising projects not meeting expectations

MicuRx shareholders Genie Pharma publicly solicit votes to oppose certain proposals

MicuRx Pharmaceuticals has signed a strategic cooperation agreement with Nanjing Haiqing Pharmaceuticals. The two parties will collaborate in areas such as market and customer network, and service value enhancement. The goal is to integrate market resources to promote the sales of the company's products in new regions and hospitals, with expected sales revenues of 260 million yuan, 388 million yuan, and 600 million yuan for the years 2026-2028, respectively. The two parties will also establish a product innovation cooperation platform, focusing on research in disease prevention and treatment, jointly developing new products, and promoting the internationalization of Chinese pharmaceutical companies

MicuRx Pharmaceuticals signed a strategic cooperation agreement with Haiqing Pharmaceuticals

MicuRx plans to raise no more than 1.033 billion yuan through a private placement to Haijing Pharmaceutical, issuing 164 million shares at a price of 6.30 yuan per share. The raised funds will be used for the company's daily research and development and operational investments. After this issuance, Haijing Pharmaceutical will become the controlling shareholder, and Zhang Xiantao will become the actual controller

MicuRx plans to raise no more than 1.033 billion yuan through a private placement to HaiJing Pharmaceutical for research and operational investment

According to the Zhitong Finance APP, MicuRx announced that the company recently received a notice regarding the shareholder reduction plan from Best Idea, JSR, and GP TMT. Shareholders Best Idea, JSR, and GPTMT plan to reduce their holdings of the company's shares by no more than 39.3363 million shares, which is no more than 6% of the company's total share capital, depending on market conditions through centralized bidding and block trading

MicuRx shareholders plan to reduce their holdings by no more than 6%

MicuRx announced that shareholders JSR Limited and Best Idea International Limited plan to participate in the pre-IPO shareholder inquiry transfer, intending to transfer a total of 22.9462 million shares, accounting for 3.50% of MicuRx's total share capital. This transfer is a private transfer, and the transferee will be institutional investors with corresponding pricing capabilities and risk tolerance, with the transfer price floor not lower than 70% of the average stock trading price over the 20 trading days prior to the issuance of the subscription invitation letter

MicuRx: Shareholders plan to transfer 3.5% of shares

MicuRx announced that its operating revenue in the first half of 2025 was 66.9698 million yuan, a year-on-year increase of 10.26%. The net loss attributable to shareholders of the listed company was 139 million yuan, compared to a net loss of 201 million yuan in the same period last year. The basic earnings per share were -0.21 yuan/share, compared to -0.31 yuan/share in the same period last year

MicuRx: Net loss of 139 million yuan in the first half of 2025

MicuRx(688373.SH)